RxDoctor Payments Data

Adeola Darden, MD

Family Medicine · Dallas, TXNPI 1043248156

Payments from drug & device makers

$4,966in general payments, 2019–2025

Across 274 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$812
  • AstraZeneca$505
  • Lilly USA, LLC$455
  • Amgen$425
  • Pfizer$353
  • GSK$334
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,960100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,966 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,432
Medicare patients
173
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$152,421
MounjaroTirzepatide57$93,019
TrulicityDulaglutide35$76,225
JardianceEmpagliflozin56$66,886
EliquisApixaban66$63,313
JanuviaSitagliptin Phosphate50$62,804
FarxigaDapagliflozin Propanediol42$51,916
RybelsusSemaglutide33$50,654
LinzessLinaclotide60$44,512
Repatha SureclickEvolocumab23$25,879
MyrbetriqMirabegron30$22,292
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$14,060
XareltoRivaroxaban13$9,265
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$7,140
Atorvastatin Calcium736$6,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$812$203,075132 claims
Lilly USA, LLCMounjaro, Trulicity$455$169,24592 claims
Boehringer IngelheimJardiance$239$66,88656 claims
PfizerEliquis$353$63,31366 claims
AstraZenecaFarxiga, Nexium, Symbicort$505$61,44770 claims
AbbVieLinzess, Synthroid$312$45,96778 claims
Astellas Pharma US IncMyrbetriq$12$22,29230 claims
Johnson & JohnsonXarelto$161$9,26513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →